RVPH · Reviva Pharmaceuticals Holdings, Inc.
$0.51
+0.01 (+1.09%)
At close · Aug 14
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt regarding the Company’s ability to continue as a going concern for a period of one year after the date the consolidated financial statements are issued. These circumstances raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the consolidated financial statements are issued.”View the 10-Q filed Aug 12, 2026
Market Cap
$6.69M
Shares
13.11M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$19.86M
+33.6%
FY2025
Operating Cash Flow
-$24.59M
+26.7%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| $372.61K | — | — | — | — | — | $1.32M | — | |
| $6.7M | $11.71M | $22.91M | $31.42M | $22.87M | $4.85M | $295.15K | $195.74K | |
| $6.78M | $8.49M | $7.89M | $8.08M | $5.36M | $5.25M | $2.14M | $181.12K | |
| $13.48M | $20.2M | $30.8M | $39.5M | $28.23M | $10.1M | $2.43M | $376.86K | |
| -$13.48M | -$20.2M | -$30.8M | -$39.5M | -$28.23M | -$10.1M | -$2.43M | -$376.86K | |
| $6573 | $13.4K | $18.5K | $33.73K | — | $0 | $1.45M | $469.37K | |
| $468.09K | $311.37K | $361.37K | $398.41K | — | — | $105.18K | $201 | |
| $467.81K | $354.02K | $899.6K | $259.75K | -$11.91K | $1.59M | -$1.35M | -$469.17K | |
| -$13.01M | -$19.85M | -$29.9M | -$39.24M | -$28.24M | -$8.52M | -$3.78M | -$846.03K | |
| $11.7K | $18.89K | $19.51K | $16.95K | $20.78K | $6004 | $800 | $800 | |
| -$13.02M | -$19.86M | -$29.92M | -$39.26M | -$28.26M | -$8.52M | -$3.78M | -$846.83K | |
| -$1.44M | — | — | — | — | — | -$545.63K | -$76.68K | |
| USD/shares | — | -$5.48 | -$17.73 | -$33.00 | -$29.00 | -$11.60 | — | — |
| shares | — | 3.63M | 1.69M | 1.19M | 975.82K | 739.54K | 153.08K | 138.42K |
| shares | — | — | — | — | — | 739.54K | 153.08K | 138.42K |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 2.39×
EV/EBIT
—
P/E (TTM)
—
Peer medians compare against the 169 similar-size Biotechnology companies (of 545 listed).